XML 33 R12.htm IDEA: XBRL DOCUMENT v3.24.0.1
Loss of Control of Bophelo Bio Science and Wellness (Pty) Ltd.
 6 Months Ended 12 Months Ended
Jun. 30, 2023
Dec. 31, 2022
Loss of Control of Bophelo Bio Science and Wellness (Pty) Ltd. [Abstract]    
Loss of Control of Bophelo Bio Science and Wellness (Pty) Ltd.

5.      Loss of Control of Bophelo Bio Science and Wellness (Pty) Ltd.

On July 26, 2022, the Company announced that the High Court of Lesotho (the “Lesotho Court”) has placed in liquidation the Company’s, wholly-owned subsidiary, Bophelo Bio Science and Wellness (Pty) Ltd. (“Bophelo”). The action to place Bophelo in liquidation was taken by the Lesotho Court pursuant to an application and request (the “Liquidation Application”) that was filed by Louisa Mojela, the former Executive Chairman of the Company, who was recently terminated as Executive Chairman of Akanda, and the Mophuti Matsoso Development Trust (“MMD Trust”). Akanda intends to convene a special committee to investigate Ms. Mojela’s actions and conduct, including actions and conduct taken by her prior to her filing of the Liquidation Application, and will pursue all of its available legal rights and remedies against Ms. Mojela and the MMD Trust for taking this unauthorized action. The Company also intends to contest and seek to reverse the determination by the Lesotho Court to place Bophelo in liquidation. In addition, Akanda will seek to recover significant loans that it has made to Bophelo to fund the execution of Bophelo’s business plan, including payment of rents and staffing costs, in the event that the Lesotho Court does not reverse its determination to place Bophelo in liquidation. Finally, Ms. Mojela has been summarily terminated as Chairman of Bophelo for Cause, as a “bad leaver”, as a result of her action to seek to place Bophelo in liquidation. Ms. Mojela has instituted legal proceedings against the Company as a result of the termination of her employment. In an action taken without the Company’s knowledge, the Lesotho Court has ordered an insolvent liquidation of Bophelo, and has appointed Mr. Chavonnes Cooper of Cape Town, South Africa, as liquidator of Bophelo for purposes of maintaining the value of the assets owned or managed by Bophelo. The order was signed by the Honorable Mr. Justice Mokhesi on July 15, 2022.

At December 31, 2022, the Company determined that it no longer controlled Bophelo Bio Science and Wellness (Pty) Ltd. as a result of the above insolvent liquidation. As a result of the loss of control, the Company derecognized all assets and liabilities at their book values on December 31, 2022 and wrote down all balances receivable from the entity to $nil. During the year ended December 31, 2022, the Company recorded a loss on loss of control of Bophelo Bio Science and Wellness (Pty) Ltd. of $2,085,624, which included $739,947 of cash held by Bophelo Bio Science and Wellness (Pty) Ltd. The Company accounted for the operating results of Bophelo Bio Science and Wellness (Pty) Ltd. as a discontinued operation during the year ended December 31, 2022 and has reclassified the operating results of Bophelo Bio Science and Wellness (Pty) Ltd as a discontinued operation for the year ended December 31, 2021.

Set out below is the financial performance and cash flow information for the years ended December 31, 2022 related to the discontinued operation:

Years ended December 31,

  

2022

Revenue

  

$

31,123

 

Operating expenses

  

 

(1,244,691

)

Other expenses

  

 

(123,033

)
   

 

(1,336,601

)

Loss on loss of control of subsidiary

  

 

(2,085,624

)

Loss on discontinued operations

  

$

(3,422,225

)
   

 

  

 

Exchange differences on translation of discontinued operations

  

$

(450,040

)

Other comprehensive income from discontinued operations

  

$

(450,040

)

Years ended December 31,

  

2022

Cash flows provided by operating activities

  

$

1,060,350

 

Cash flows used in investing activities

  

 

(1,003,529

)

Cash flows provided by (used in) financing activities

  

 

(95,696

)

Effects of exchange rate changes on cash and cash equivalents

  

 

18,909

 

Net change in cash provided by (used in) the subsidiary

  

$

(19,966

)
   

 

  

 

Carrying amount of net assets immediately prior to loss of control of subsidiary

  

$

2,375,840

 

Reclassification of foreign currency translation reserve

  

 

(290,216

)

Loss on loss of control of subsidiary

  

$

2,085,624

 

As at December 31, 2022, the carrying amounts of assets and liabilities of Bophelo Bio Science and Wellness (Pty) Ltd were as follows:

Cash

  

$

739,947

Accounts receivable

  

 

21,854

Prepayments

  

 

578,070

Property, plant and equipment

  

 

1,887,435

Right-of-use assets

  

 

1,745,205

Intangible assets

  

 

210,402

Total assets

  

$

5,182,913
   

 

  

Trade and other payables

  

 

115,120

Lease liability

  

 

2,375,590

Long-term debt

  

 

316,363

Total liabilities

  

$

2,807,073

Net assets

  

$

2,375,840

5.      Loss of Control of Bophelo Bio Science and Wellness (Pty) Ltd.

On July 26, 2022, the Company announced that the High Court of Lesotho (the “Lesotho Court”) has placed in liquidation the Company’s, wholly-owned subsidiary, Bophelo Bio Science and Wellness (Pty) Ltd. (“Bophelo”). The action to place Bophelo in liquidation was taken by the Lesotho Court pursuant to an application and request (the “Liquidation Application”) that was filed by Louisa Mojela, the former Executive Chairman of the Company, who was recently terminated as Executive Chairman of Akanda, and the Mophuti Matsoso Development Trust (“MMD Trust”). Akanda intends to convene a special committee to investigate Ms. Mojela’s actions and conduct, including actions and conduct taken by her prior to her filing of the Liquidation Application, and will pursue all of its available legal rights and remedies against Ms. Mojela and the MMD Trust for taking this unauthorized action. The Company also intends to contest and seek to reverse the determination by the Lesotho Court to place Bophelo in liquidation. In addition, Akanda will seek to recover significant loans that it has made to Bophelo to fund the execution of Bophelo’s business plan, including payment of rents and staffing costs, in the event that the Lesotho Court does not reverse its determination to place Bophelo in liquidation. Finally, Ms. Mojela has been summarily terminated as Chairman of Bophelo for Cause, as a “bad leaver”, as a result of her action to seek to place Bophelo in liquidation. Ms. Mojela has instituted legal proceedings against the Company as a result of the termination of her employment. In an action taken without the Company’s knowledge, the Lesotho Court has ordered an insolvent liquidation of Bophelo, and has appointed Mr. Chavonnes Cooper of Cape Town, South Africa, as liquidator of Bophelo for purposes of maintaining the value of the assets owned or managed by Bophelo. The order was signed by the Honorable Mr. Justice Mokhesi on July 15, 2022.

At December 31, 2022, the Company determined that it no longer controlled Bophelo Bio Science and Wellness (Pty) Ltd. as a result of the above insolvent liquidation. As a result of the loss of control, the Company derecognized all assets and liabilities at their book values on December 31, 2022 and wrote down all balances

receivable from the entity to $nil. During the year ended December 31, 2022, the Company recorded a loss on loss of control of Bophelo Bio Science and Wellness (Pty) Ltd. of $2,085,624, which included $739,947 of cash held by Bophelo Bio Science and Wellness (Pty) Ltd. The Company accounted for the operating results of Bophelo Bio Science and Wellness (Pty) Ltd. as a discontinued operation during the year ended December 31, 2022 and has reclassified the operating results of Bophelo Bio Science and Wellness (Pty) Ltd as a discontinued operation for the year ended December 31, 2021.

Set out below is the financial performance and cash flow information for the years ended December 31, 2022 and 2021 related to the discontinued operation:

Years ended December 31,

 

2022

 

2021

Revenue

  

$

31,123

 

  

$

—

 

Operating expenses

  

 

(1,244,691

)

  

 

(3,550,441

)

Other expenses

  

 

(123,033

)

  

 

(2,107,053

)
   

 

(1,336,601

)

  

 

(5,657,494

)

Loss on loss of control of subsidiary

  

 

(2,085,624

)

  

 

—

 

Loss on discontinued operations

  

$

(3,422,225

)

  

$

(5,657,494

)
   

 

  

 

  

 

  

 

Exchange differences on translation of discontinued operations

  

$

(450,040

)

  

$

636,135

 

Other comprehensive income from discontinued operations

  

$

(450,040

)

  

$

636,135

 
   

 

  

 

  

 

  

 

Cash flows provided by operating activities

  

$

1,060,350

 

  

$

7,414,607

 

Cash flows used in investing activities

  

 

(1,003,529

)

  

 

(570,864

)

Cash flows provided by (used in) financing activities

  

 

(95,696

)

  

 

6,832,634

 

Effects of exchange rate changes on cash and cash equivalents

  

 

18,909

 

  

 

(1,263

)

Net change in cash provided by (used in) the subsidiary

  

$

(19,966

)

  

$

9,846

 
   

 

  

 

  

 

  

 

Carrying amount of net assets immediately prior to loss of control of
subsidiary

  

$

2,375,840

 

  

$

—

 

Reclassification of foreign currency translation reserve

  

 

(290,216

)

  

 

—

 

Loss on loss of control of subsidiary

  

$

2,085,624

 

  

$

—

 

As at December 31, 2022, the carrying amounts of assets and liabilities of Bophelo Bio Science and Wellness (Pty) Ltd were as follows:

Cash

  

$

739,947

Accounts receivable

  

 

21,854

Prepayments

  

 

578,070

Property, plant and equipment

  

 

1,887,435

Right-of-use assets

  

 

1,745,205

Intangible assets

  

 

210,402

Total assets

  

$

5,182,913

Trade and other payables

  

 

115,120

Lease liability

  

 

2,375,590

Long-term debt

  

 

316,363

Total liabilities

  

$

2,807,073

Net assets

  

$

2,375,840